Reperfusion and revascularization by percutaneous coronary intervention (PCI) under protection by anticoagulant and antiplatelet agents have markedly improved the clinical outcome of patients presenting with an acute coronary syndrome (ACS). 1,2 Balancing the risk of an acute coronary thrombosis against bleeding risk is critical in ACS patients as these complications have a significant negative impact both on early in-hospital but also on the late clinical outcome. Many bleeding complications are directly related to the use of a femoral access site and can be avoided by more systematically using a radial access site. This issue bundles a series of clinical studies that assessed different aspects of antithrombotic therapy and the effect of vascular access site in the management of ACS.
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Several studies have suggested that the use of bivalirudin is associated with a lower risk for bleeding complications compared to an anticoagulant regimen with unfractionated heparin in combination with potent IIb-IIIa receptor antagonists. [3] [4] [5] In a substudy of the VALIDATE-SWEDEHEART trial 6 bivalirudin, as compared to unfractionated heparin in monotherapy did not reduce the composite endpoint of all-cause death, myocardial infarction or major bleeding during 180 days of follow-up in non-ST-elevation myocardial infarction patients receiving antiplatelet therapy with modern P2Y12-inhibitors and in whom PCI was performed predominantly through radial access. 7 These findings are completely in line with the results of the main trial and the MATRIX trial. 8 A second substudy of the VALIDATE-SWEDEHEART trial assessed the impact of sex on the clinical outcome after anticoagulant therapy with bivalirudin as compared to unfractionated heparin in monotherapy in patients treated by PCI for acute myocardial infarction. 9 In contrast with men, women showed a lower risk of adverse outcomes after bivalirudin treatment, mainly due to a significant reduction of major bleeding complications. An older age, a lower body weight and a higher CRUSADE bleeding score in women were the most significant differences that may explain the better clinical outcome observed with bivalirudin.
A third substudy of the VALIDATE-SWEDEHEART trial analyzed the impact of vascular access site on the composite endpoint at 180 days. 10 Patients with PCI performed through radial access showed compared to patients with femoral access a 47% reduction of the composite endpoint irrespective of the anticoagulation strategy used.
Residual platelet reactivity under dual antiplatelet therapy with clopidogrel and aspirin is a predictor of poor prognosis in ACS patients. Upon initiation of the coagulation cascade activation of factor IX leads to the downstream generation of thrombin, a potent activator of platelet aggregation. Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduced platelet reactivity in vitro and residual platelet aggregation in ACS patients. 11 These results suggest that treatment with factor IXa inhibitors might provide additional peri-interventional antithrombotic protection of ACS patients undergoing PCI.
A report based on an extensive population-based ACS registry in Italy shows that the prescription of recommended dual antiplatelet agent therapy and its continuation during long-term follow-up is very suboptimal and leads to increased healthcare costs mainly related to rehospitalizations. 12 These study results indicate that before considering using innovative and probably more expensive antiplatelet therapies, we should focus first on improving the implementation of guideline-recommended therapies.
Patients with diabetes show an accelerated and more diffuse development of coronary atherosclerosis and have an increased risk of atherothrombotic complications. The latter is primarily related to the presence of hyperreactive platelet dysfunction in diabetes mellitus. 13 In the setting of ACS, this results in an increased incidence of short and Optimal antithrombotic therapy and vascular access site in the management of acute coronary syndromes long-term recurrent ischemic events requiring prolonged and more potent antiplatelet therapy. Both prasugrel and ticagrelor have been shown to improve outcomes in ACS compared to clopidogrel. 14, 15 This benefit is most substantial in diabetic patients, mainly when using prasugrel. 16 The direct-acting ticagrelor may lead to higher levels of platelet inhibition than prasugrel 17 what has led to speculation which antiplatelet to prefer in diabetic ACS patients. 18 In a propensity-matched substudy of the RENAMI (REgistry of New Antiplatelets in patients with Myocardial Infarction) registry the safety and efficacy of prasugrel and ticagrelor were compared in diabetic ACS patients treated by PCI. 19 The main conclusion was that both agents were equally effective in reducing net and major adverse cardiovascular events. Ticagrelor resulted in a significant reduction in allcause death and bleeding, without differences in recurrent ischemic events, which needs confirmation by dedicated randomized controlled trials.
The optimal timing of coronary artery bypass grafting (CABG) after P2Y12 receptor antagonist discontinuation in ACS patients remains an unsolved clinical problem. In a retrospective study of ACS patients requiring emergent or urgent CABG, P2Y12 receptor antagonist discontinuation less than 72 hours resulted in higher rates of bleeding and ischemic complications. 20 Patients who underwent CABG between 3 to 5 days after discontinuation showed similar complication rates as when CABG was performed after five days. The results of this study need confirmation by a larger randomized prospective trial.
In the last part of this issue, the reader will find a metaanalysis on the efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease, 21 a literature review on the optimal location and duration of hospitalization following primary PCI for ST-elevation myocardial infarction 22 and a study based on an extensive Canadian registry on the clinical outcome of medically managed patients with acute myocardial infarction. 23 
